Comparative Pharmacology
Head-to-head clinical analysis: FIASP versus FIASP FLEXTOUCH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FIASP versus FIASP FLEXTOUCH.
FIASP vs FIASP FLEXTOUCH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FIASP is an insulin aspart formulation with faster absorption due to added L-arginine and niacinamide. It activates insulin receptor tyrosine kinase, promoting glucose uptake via GLUT4 translocation.
Insulin analog that binds to insulin receptors, lowering blood glucose by facilitating cellular uptake of glucose and inhibiting hepatic glucose production.
Subcutaneous injection at mealtimes, dose individualized. Typical starting total daily dose 0.5-1 unit/kg/day, given as 50% bolus and 50% basal. Bolus dose: 1-2 units or 0.1-0.2 units/kg per meal.
Subcutaneous injection at mealtime, 0.2-0.4 units/kg per dose, with total daily dose individualized; typically 50-70% of total daily insulin as bolus, remainder as basal.
None Documented
None Documented
0.7-1.0 hours (ultra-rapid acting insulin; terminal half-life from subcutaneous absorption, not intravenous elimination).
Terminal elimination half-life is approximately 1.3 hours (range 1-1.5 hours) in healthy subjects, corresponding to the rapid clearance of monomeric insulin aspart. This short half-life supports prandial dosing to cover meal-related glucose excursions.
Renal: Approximately 60-80% of insulin aspart is excreted via the kidneys following degradation. Fecal/biliary excretion accounts for <10%.
Renal: approximately 60% of administered insulin is excreted via the kidneys, with the remainder undergoing hepatic metabolism and biliary excretion.
Category C
Category C
Insulin Analogue
Insulin Analogue